ArticleBMJ open2025
Platelet-to-albumin ratio as an indicator for Crohn's disease activity and severity: a multicentre cross-sectional study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDisease activity assessment is important for Crohn's disease (CD) management, since it involves the initial and subsequent therapeutic schedule. The purpose of this study is to identify a portable and reliable indicator for assessing and predicting activity and severity of CD.
designA multicentre, cross-sectional, diagnosis-based study. Data were obtained retrospectively from clinical records.
settingPatient data for the development cohort and internal validation cohort were collected from the Department of Gastroenterology, Xiangya Hospital, Central South University between January 2017 and June 2021. Patient data for the external validation cohort were collected from the Department of Gastroenterology, Xiangtan Central Hospital between January 2022 and April 2024.
participantsInpatients diagnosed with CD were potential participants, and those with CD who also had other autoimmune diseases, malignant tumours, pregnancy or lactation were excluded. We identified 224 patients in the development cohort, 96 patients in the internal validation cohort and 80 patients in the external validation cohort. OUTCOME MEASURE: Demographic data and laboratory examination results were collected and seven integrated indices were established. Mann-Whitney U test, Kruskal-Wallis K test, χ
resultsIn the development cohort, platelet-to-albumin ratio (PAR) had the largest area under the curve (AUC) in prediction of activity (AUC of 0.753 (0.687-0.819), sensitivity 73.0%, specificity 68.4%, cut-off value 8.02) and was the only possible alternative in prediction of severity (AUC of 0.770 (0.693-0.848), sensitivity 81.2%, specificity 68.4%, cut-off value 9.71). Moreover, PAR demonstrated coherence in the internal validation cohort, effectively predicting activity (AUC 0.737 (0.639-0.835), sensitivity 65.7%, specificity 79.3%, positive predictive value (PPV) 88.0%, negative predictive value (NPV) 50.0%) and severity (AUC 0.720 (0.591-0.848), sensitivity 88.5%, specificity 77.4%, PPV 76.7%, NPV 64.9%). Furthermore, it showed generalisability in the external validation cohort for predicting activity (AUC 0.661 (0.536-0.785), sensitivity 61.9%, specificity 70.6%, PPV 88.6%, NPV 33.3%) and severity (AUC 0.752 (0.619-0.884), sensitivity 73.1%, specificity 64.9%, PPV 59.4%, NPV 77.4%).
conclusionsPAR could be a portable index to assess the activity and severity of CD. Several limitations of this study, such as the limited sample size and potential biases, should be overcome in the future via more extensive validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.